Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: A multi-center study

Tullio Florio, Federica Barbieri, Renato Spaziante, Gianluigi Zona, Leo J. Hofland, Peter M. Van Koetsveld, Richard A. Feelders, Günter K. Stella, Marily Theodoropoulou, Michael D. Culler, Jesse Dong, John E. Taylor, Jacques Pierre Moreau, Alexandru Saveanu, Ginette Gunz, Henry Dufour, Philippe Jaquet

Research output: Contribution to journalArticle

Abstract

Dopamine D2 and somatostatin receptors (sstrs) were reported to affect non-functioning pituitary adenoma (NFPA) proliferation in vitro. However, the reported results differ according to the experimental conditions used. We established an experimental protocol allowing reproducible evaluation of NFPA cell proliferation in vitro, to test and compare the antiproliferative effects of dopamine and somatostatin analogs (alone or in combination) with the activity of the dopamine-somatostatin chimeric molecule BIM-23A760. The protocol was utilized by four independent laboratories, studying 38 fibroblast-deprived NFPA cell cultures. Cells were characterized for GH, POMC, sstr1-sstr5, total dopamine D2 receptor (D2R) (in all cases), and D2 receptor long and short isoforms (in 15 out of 38 cases) mRNA expression and for α-subunit, LH, and FSH release. D2R, sstr3, and sstr2 mRNAs were consistently observed, with the dominant expression of D2R (2.9 ± 2.6 copy/copy β-glucuronidase; mean ± s.E.M.), when compared with sstr3 and sstr2 (0.6 ± 1.0 and 0.3 ± 0.6 respectively). BIM-23A760, a molecule with high affinity for D2R and sstr2, significantly inhibited [3H]thymidine incorporation in 23 out of 38 (60%) NFPA cultures (EC50 = 1.2 pM and Emax = -33.6 ± 3.7%). BIM-23A760 effects were similar to those induced by the selective D2R agonist cabergoline that showed a statistically significant inhibition in 18 out of 27 tumors (compared with a significant inhibition obtained in 17 out of 27 tumors using BIM-23A760, in the same subgroup of adenomas analyzed), while octreotide was effective in 13 out of 27 cases. In conclusion, superimposable data generated in four independent laboratories using a standardized protocol demonstrate that, in vitro, chimeric dopamine/sstr agonists are effective in inhibiting cell proliferation in two-thirds of NFPAs.

Original languageEnglish
Pages (from-to)583-596
Number of pages14
JournalEndocrine-Related Cancer
Volume15
Issue number2
DOIs
Publication statusPublished - Jun 2008

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: A multi-center study'. Together they form a unique fingerprint.

  • Cite this

    Florio, T., Barbieri, F., Spaziante, R., Zona, G., Hofland, L. J., Van Koetsveld, P. M., Feelders, R. A., Stella, G. K., Theodoropoulou, M., Culler, M. D., Dong, J., Taylor, J. E., Moreau, J. P., Saveanu, A., Gunz, G., Dufour, H., & Jaquet, P. (2008). Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: A multi-center study. Endocrine-Related Cancer, 15(2), 583-596. https://doi.org/10.1677/ERC-07-0271